myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

2024 Los Angeles Patient and Family Conference

The time is now to save your seat for the 2024 Patient and Family Conference in Los Angeles!

Plan to attend on April 13, 2024, in Los Angeles, CA, in partnership with City of Hope (Duarte, CA) - Register Here

Register Now for 2024 Los Angeles Patient and Family Conference
Event Date: 
Sat, 04/13/2024 - 7:45am (EDT)
Conference Event Type: 

Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy

Author(s): 
Avenoso D, Serpenti F, Slonim LB, Bouziana S, Dazzi F, Hannah G, Kenyon M, Mehra V, Kulasekararaj A, Krishamurthy P, Shah MN, Lionel S, Pagliuca A, Potter V
Primary Author: 
Avenoso D
Journal Title: 
Mediterranean Journal of Hematology and Infectious Diseases
Original Publication Date: 
Jan 2024

Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant

Bone Marrow Disease(s): 

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author(s): 
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U
Primary Author: 
Zeidan AM
Journal Title: 
Lancet Hematology
Original Publication Date: 
Jan 2024

Background: Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic

Bone Marrow Disease(s): 

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Author(s): 
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE
Primary Author: 
Garcia-Manero G
Journal Title: 
Lancet Hematology
Original Publication Date: 
Jan 2024

Background: The DNA methyltransferase inhibitors

Bone Marrow Disease(s): 

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Author(s): 
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS
Primary Author: 
Platzbecker U
Journal Title: 
Lancet
Original Publication Date: 
Jan 2024

Background: Unmet medical needs remain in patients with

Bone Marrow Disease(s): 
Share with addtoany.com.